FDA wants male breast cancer patients

Share this article:

The FDA wants drugmakers to make men a regular part of breast cancer clinical trials. Regulatory Focus reports that the FDA is encouraging manufacturers to bring in male test patients “unless there is a valid scientific reason not to.”

RF says that although men comprise around 1% of breast cancer cases, the cancer has a “disproportionally negative effect on men.” One reason: men don't usually associate a lump with breast cancer, which means a later diagnosis and delayed treatment.

FDA's science lead also says men need to be part of breast cancer clinical trials because while postmenopausal women typically respond to aromatase inhibitors with tamoxifen as a second-line treatment, the reverse is true of male patients.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.